Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Announces $1.0B Exchangeable Senior Notes Offering and Concurrent Share Repurchases
Summary
On September 3, 2024, Jazz Pharmaceuticals plc announced the completion of a private offering of $1.0 billion aggregate principal amount of 3.125% exchangeable senior notes due 2030, with an option for additional purchases of up to $150 million by initial purchasers. The Company estimates net proceeds of approximately $981 million, which will be used to prepay term loans and for general corporate purposes. Concurrently, the Company repurchased approximately $150 million of its ordinary shares from purchasers of the notes at a price of $109.32 per share, reducing the remaining amount authorized under its share repurchase program. The notes are exchangeable under certain conditions, and the Issuer may redeem the notes under specific circumstances. The offering is exempt from registration under Rule 144A of the Securities Act of 1933.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (3)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement